Sentences with phrase «hiv vaccine efficacy»

Randomized, Double - Blind Evaluation of Late Boost Strategies for HIV - Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Results from the RV144 trial, reported in 2009, provided the first signal of HIV vaccine efficacy: a 31 percent reduction in HIV infection among vaccinees.

Not exact matches

In collaboration with many researchers (graduate students, postdocs, and faculty elsewhere), we have examined the role of cross-immunity on the evolution and dynamics of influenza; the impact of behavioral changes, long periods of infectiousness, variable infectivity, co-infections, prostitution, social networks, and vaccine efficacy on HIV dynamics; the role of exogenous re-infection, variable progression rates, vaccination, public transportation, close and casual contacts on tuberculosis dynamics and control; the impact of life - history vector dynamics on dengue epidemics; and on the identification of time - response scales for epidemics of foot and mouth disease.

SEATTLE, WA and DURHAM, NC — The HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) today announced the initiation of HVTN 704 / HPTN 085, also known as Antibody Mediated Prevention (AMP) or the AMP Study, a Phase 2b clinical trial to evaluate the safety and efficacy of VRC01, a broadly neutralizing monoclonal antibody (bnAb).

The HVTN's mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.

In the RV144 vaccine trial, led by the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research, the efficacy at 3.5 - years was 31.2 %; however, a higher early effect (60 %) was seen at 12 months.

Currently, RV144 vaccine from Thailand is the only HIV preventive vaccine htat has shown efficacy in the last 30 years of vaccine research.

We are in the midst of an unprecedented time in HIV vaccine research; we have four concurrent efficacy trials underway, which will collectively enroll 12,200 volunteers in the search for an HIV vaccine over the next few years.

«This finding is consistent with a hypothesis generated out of the follow - up studies to the RV144 HIV vaccine trial in Thailand that showed the first efficacy in humans,» noted COL Nelson Michael, Director of the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

It is the only HIV vaccine to show modest efficacy in preventing infections.

It played a critical role landmark RV144 «Thai Study,» a 16,000 person study which was the only HIV vaccine trial to date to demonstrate modest (31 %) efficacy of a potential HIV vaccine, and the follow - on studies on the RV144 correlates of risk.

However, the scientific community world over is excited regarding the new discovery of certain biomarkers that would provide clue to improve the efficacy of HIV vaccines.

The findings were published In the New England Journal of Medicine (NEJM) and concluded that vaccines designed to induce higher levels of V1V2 antibodies and lower Env - specifc IgA antibodies could result in improved efficacy against HIV - 1 infection.

Sanjay Gurunathan from Sanofi Pasteur, manufacturer of one of the vaccines used in RV144, said a new partnership of the US National Institute of Allergy and Infectious Diseases, The Bill & Melinda Gates Foundation, HIV Vaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pVaccine Trials Network, US Military HIV Research Program (MHRP), and Sanofi Pasteur — known as the Pox Protein Public Private Partnership, or P5 — will aim to increase vaccine efficacy from the 31.2 percent of the RV144 trial to 50 pvaccine efficacy from the 31.2 percent of the RV144 trial to 50 percent.

Although the efficacy in the Thai study was not high enough to warrant the vaccine's use as a public health tool, the results are helping scientists develop more effective HIV vaccine candidates.

At the first plenary session of AIDS Vaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infVaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infvaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infection.

Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost vaccine candidates initially tested in the RV144 trial in Thailand — the only HIV vaccine trial to date to show any efficacy — induced cross-clade immune responses in a Phase I safety trial conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai volunteers.

MHRP is proud to have led a large group that executed the landmark RV144 vaccine trial, the first study to show efficacy in preventing HIV infection.